Instructions for uploading your PowerPoint presentation and survey:
The PPT attachment needs to be the first node under the report (i.e., it should appear before your survey).
Name the PPT in the same fashion as you want it displayed on the Platform. The name will be displayed exactly as it appears in the filename. We recommend using the following naming convention for the PPT filename: Indication – Product – Report. The name in the “Title” field in the Form tab should be the same as the PPT.
Select the “Embed” option in the "EmbedAttachment" field for the PPT attachment. This will ensure that it is embedded on the Platform.
The survey should be uploaded to Kentico as a File Attachment after the PPT attachment. The survey should be in PDF in the DRG survey document. The name in the “Title” field in the Form tab should be the same as the survey.
Select the “Sidebar” option in the "EmbedAttachment" field for the survey attachment.
For the Abstract field: Copy/Paste the key inputs from the product brochure, per guidance from Marketing.
Osteoarthritic (OA) pain is the second-largest segment of the chronic pain therapy market and is expected to grow, driven by an aging population and the increasing prevalence of obesity. Yet a comprehensively effective and tolerable analgesic class alternative has not become available for this indication in nearly two decades. A successful launch of a new analgesic requires a deep understanding of current treatment patterns in this highly generic market. Over the past few years, several new therapies have launched for OA pain, providing incremental safety, tolerability, and/or dosing benefits to overcome drawbacks of the current standards of care─nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics─but how have agents in these drug classes, particularly brand-only products, fared in this highly generic market in which cost-effectiveness is a primary driver of coverage?
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OA pain patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OA pain patients?
- How have branded agents such as abuse-deterrent opioid analgesics been integrated into the treatment algorithm, and what is their source of business?
- What percentage of OA pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of OA pain patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Osteoarthritic Pain - Current Treatment - Treatment Algorithms Claims Data Analysis (US)
- Treatment Algorithms CDA Osteoarthritic Pain US May 2019
Author(s): Joyce Spadafora, ALM
Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content.
Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a B.S in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.